Gray stressed the effects are quite modest and only really effective at the really early stages of Alzheimer’s disease (and don’t work for vascular dementia ... as three months. The most commonly ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in ...

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show ...

CADASIL is a brain disease involving genetic mutations, stroke, and dementia. Learn about symptom progression and ongoing ...

A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

Frontotemporal dementia hit headlines ... if it’s proven to be effective, will be very cheap to manufacture.” He said the fact multiple companies could produce the drug would also help ensure ...

Researchers from DZNE and Otto von Guericke University Magdeburg have identified individuals with increased risk for dementia ...

The rate of antipsychotic drug use in nursing homes has remained stubbornly high. Experts are concerned about misuse.

Anxiety and depression are significant risk factors for AD, and conversely, AD increases the likelihood of developing these psychiatric conditions. A systematic review of 14,760 studies showed ...